US 12,214,037 B2
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
Jennifer Brogdon, Sudbury, MA (US); Eugene Choi, Cambridge, MA (US); Hilmar Erhard Ebersbach, Basel (CH); David Jonathan Glass, Cambridge, MA (US); Heather Huet, Arlington, MA (US); Carl H. June, Merion Station, PA (US); Joan Mannick, Cambridge, MA (US); Michael C. Milone, Moorestown, NJ (US); Leon Murphy, Cambridge, MA (US); Gabriela Plesa, Blue Bell, PA (US); Celeste Richardson, Cambridge, MA (US); Marco Ruella, Ardmore, PA (US); Reshma Singh, Cambridge, MA (US); Yongqiang Wang, Shanghai (CN); and Qilong Wu, Shanghai (CN)
Assigned to Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and Novartis AG, Basel (CH)
Filed on Jun. 25, 2021, as Appl. No. 17/359,211.
Application 17/359,211 is a division of application No. 16/197,565, filed on Nov. 21, 2018, granted, now 11,084,880.
Application 16/197,565 is a division of application No. 14/805,193, filed on Jul. 21, 2015, granted, now 10,174,095, issued on Jan. 8, 2019.
Claims priority of application No. PCT/CN2014/082586 (WO), filed on Jul. 21, 2014; and application No. PCT/CN2014/090501 (WO), filed on Nov. 6, 2014.
Prior Publication US 2022/0064316 A1, Mar. 3, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); A61K 35/12 (2015.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); C12N 5/00 (2006.01); C12N 15/63 (2006.01)
CPC A61K 39/4611 (2023.05) [A61K 39/39558 (2013.01); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); C07K 16/2878 (2013.01); A61K 35/12 (2013.01); A61K 38/177 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07H 21/04 (2013.01); C07K 14/705 (2013.01); C07K 14/70578 (2013.01); C07K 14/7151 (2013.01); C07K 19/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01); C12N 5/00 (2013.01); C12N 15/63 (2013.01)] 16 Claims
 
1. A method of providing an anti-tumor immunity in a mammal comprising administering to the mammal an effective amount of a cell comprising an isolated nucleic acid molecule encoding a chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an anti-B-cell maturation antigen (BCMA) binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises:
(i) a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 394, a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 434, and a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 474, a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 514, a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 554, and a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 594;
(ii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 674, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 714, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 754, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 794, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 834; or
(iii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 874, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 914, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 954, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 994, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1034, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1074; and
wherein the encoded intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.